Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/ tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients

Antiviral Therapy

Volumn 11, Issue 6, 2006, Pages 827-830

  Masquelier, Bernard ^a,b   Neau, Didier ^a   Boucher, Sébastien ^a,b   Lavignolle Aurillac, Valérie ^c   Schrive, Marie Hélène ^a,b   Recordon Pinson, Patricia ^a,b   Ragnaud, Jean Marie ^a   Fleury, Hervé ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR DISOPROXIL;

ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PILOT STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE;

EID: 33749339599     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19:135-140.
2. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
3. Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6:291-301.
4. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 51.
5. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
6. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr 2003; 33:15-21.
7. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846.
8. Masquelier B, Tamalet C, Montes B, et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 2004; 9:315-323.
9. Boucher S, Recordon-Pinson P, Ragnaud J, Dupon M, Fleury H, Masquelier B. K65R prevalence and genotypic patterns in patients failing tenofovir DF-containing regimens. 2nd European HIV Drug Resistance Workshop: From Basic Science to Clinical Implications. 11-13 March 2004, Rome, Italy. Abstract 51:P4.9.
10. Parikh U, Koontz D, Sluis-Cremer N, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, California. Abstract 54.
11. White K, Margot N, Chen JM, et al. The HIV-1 K65R RT mutant utilizes a combination of decreased incorporation and decreased excision to evade NRTI. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, California. Abstract 55.
12. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Eng J Med 2001; 344:472-480.
13. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
14. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18:227-235.
15. Kaleebu P, and the DART Trial Team. 48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial. 3rd International AIDS Society Conference on Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brasil,. Abstract LB0203